In a pooled analysis of 2310 patients with breast cancer that received neoadjuvant therapy, Denkert et al. showed patients with HER2-low tumors had longer overall survival (OS) rates, relative to those with HER2-zero disease (3-year OS rate was 85.8% vs 91.6%, p = 0.0016) (18). This evidence concerns the gene ERBB2 and breast carcinoma.